drugset / Trial / NCT06036602
Monovalent Chimpanzee Adenoviral-Vectored Sudan Ebolavirus Vaccine in Healthy Adults
Phase 2
Completed
125 enrolled
Albert B. Sabin Vaccine Institute
Biomedical Advanced Research and Development Authority · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral-Vectored Sudan Ebolavirus Vaccine in Healthy Adults
Timeline
- Start
- 2024-07-15
- Primary completion
- 2025-11-08
- Completion
- 2025-11-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | cAD3-Sudan Ebolavirus Vaccine | Vaccine | 1e+11 unknown | Intramuscular |